JPMorgan keeps Sell target for Fresenius Medical Care stock at EUR 32.30

Published on 10/19/2026 at 09:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care stock costs EUR 39.45 on October 19, 2026, 0.23 percent below Xetra. Q2 revenue rose 1.40 percent to EUR 4.86 billion.

Leadership and earnings ahead

JPMorgan kept its EUR 32.30 Sell target on October 19, 2026.
Second-quarter revenue reached EUR 4.86 billion, up 1.40 percent year over year.
Fresenius Medical Care stock trades at EUR 39.45 at 9:18 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.23 percent below the Xetra close of October 16, 2026.
Third-quarter results are scheduled for November 3, 2026.

Pop-Art-Comic einer stilisierten Niere mit blauen Wassertropfen und Schriftzug CARE im Lichtenstein-Stil — Eine lebhafte Pop-Art-Illustration einer stilisierten Niere mit blauen Wassertropfen und der Aufschrift 'CARE' im Comic-Sprechblasen-Stil – eine kreative Interpretation des Kernthemas von Fresenius Medical Care AG (ISIN DE0005785802), Illustration mit AI erstellt.

Fresenius Medical Care stock trades at EUR 39.45 at Lang & Schwarz on October 19, 2026 at 9:18 a.m. CEST, 0.23 percent below the Xetra close of October 16, 2026 at EUR 39.54. JPMorgan analyst David Adlington kept a Sell rating and a EUR 32.30 target on October 19, 2026, according to MarketScreener.

Target stays below the quote

The target is EUR 7.15 below the Lang & Schwarz price, a gap of 18.10 percent based on the target. The rating therefore puts the current valuation in direct contrast with the companys operating progress, but it does not represent a new target change.

Fresenius Medical Care reported second-quarter 2026 revenue of EUR 4.86 billion, up 1.40 percent from the second quarter of 2025. Net income reached EUR 218.0 million, down 3.20 percent year over year, while the profit margin declined to 4.50 percent from 4.70 percent, according to Simply Wall St.

Three events shape the stock

On August 4, 2026, second-quarter revenue reached EUR 4.86 billion and earnings per share came in at EUR 0.81, according to Simply Wall St. On October 7, 2026, the company announced that Shervin J. Korangy would become CEO and chair of the Management Board on October 12, 2026, according to Fresenius Medical Care. On October 19, 2026, JPMorgan maintained its Sell rating and EUR 32.30 target.

What dates matter next?

Fresenius Medical Care is scheduled to publish third-quarter 2026 results on November 3, 2026, followed by the quarterly financial report on November 6, 2026, according to the companys investor calendar. The next report will show whether the 23.00 percent second-quarter operating income growth cited in recent coverage can offset the margin pressure reported for the period.

Leadership meets a cautious target

The company has a market capitalization of EUR 10.5 billion as of October 19, 2026. Its EUR 34.57 to EUR 47.54 52-week range leaves the current quote 17.04 percent below the high, while the DAX-listed business enters its next reporting date with leadership responsibility transferred to Korangy.

Fresenius Medical Care was trading at EUR 39.45 at Lang & Schwarz on October 19, 2026 at 9:18 a.m. CEST, 0.23 percent below the Xetra close of October 16, 2026 at EUR 39.54. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.